Recent filings detail multiple transactions involving David Thomson, Executive Vice President, General Counsel & Secretary at MannKind Corp (NASDAQ:MNKD). On May 12, 2026, Mr. Thomson reported the sale of 3,033 shares of MannKind's common stock. This disposition generated a total value of $9,978 for him, with the weighted average selling price calculated at $3.29 per share. The individual sales contributing to this transaction took place within a relatively narrow range, specifically between $3.25 and $3.34 per share.
It is important to note that this particular sale was conducted under the framework of a Rule 10b5-1 trading plan. This type of plan was initially established on August 27, 2025, providing a structured mechanism for the transaction.
Furthermore, another significant stock movement occurred shortly before the previous one. On May 11, 2026, Mr. Thomson disposed of an additional 12,387 shares of MannKind common stock. This larger sale was valued at $43,602 and executed at a price point of $3.52 per share. The source material clarifies that these specific shares were withheld by the company to satisfy tax obligations associated with the vesting of Restricted Stock Units (RSUs) that had been originally granted on May 10, 2022.
Following both reported transactions, David Thomson's direct holdings in MannKind Corp common stock stand at 826,299 shares. Beyond these personal sales activities, the company recently released its first-quarter earnings report for 2026. This financial update indicated a 15% year-over-year expansion in revenue, reaching a total of $90 million.
The primary driver cited for this robust increase in top-line revenue was the inclusion of FUROSCIX revenues. These revenues stemmed from the recent acquisition of scPharmaceuticals by MannKind Corporation. While the company achieved significant growth in revenue, the financial performance also presented a mixed picture. Despite the revenue expansion, MannKind reported a non-GAAP net loss equivalent to $0.02 per share. This figure fell slightly short of the consensus forecasted Earnings Per Share (EPS) of -$0.01.
The market's reaction to these earnings results was noted, though the focus here remains on the underlying financial movements and strategic developments within the firm. The continuous acquisition activities undertaken by MannKind are highlighted as being pivotal in shaping the company’s overall financial landscape. For investors analyzing MNKD, understanding the ongoing efforts to integrate diverse new revenue streams through strategic acquisitions is crucial.
Risks
- The company reported a non-GAAP net loss of $0.02 per share, which missed the forecasted EPS of -$0.01, indicating potential pressure on profitability despite revenue gains.
- Reliance on acquisitions for revenue growth: The significant increase in revenue was primarily driven by the inclusion of FUROSCIX revenues from the scPharmaceuticals acquisition. Continued successful integration and monetization of these acquired units are critical to sustained financial health.
More from Insider Trading